Figure 1. Research Method Flow Chart 12
Figure 2. Breakdown of Primary Research 14
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 16
Figure 4. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 18
Figure 5. Europe Pharmacogenomics Market, 2019-2030, $ mn 21
Figure 6. An Overall Process of How Pharmacogenomics Functions in a Clinical Practice 23
Figure 7. Impact of COVID-19 on Business 25
Figure 8. Primary Drivers and Impact Factors of Europe Pharmacogenomics Market 27
Figure 9. World Top 10 Causes of Deaths, 2016 30
Figure 10. Primary Restraints and Impact Factors of Europe Pharmacogenomics Market 31
Figure 11. Consecutive Phases and Associated Challenges in Pharmacogenomics 33
Figure 12. Investment Opportunity Analysis 35
Figure 13. Porter’s Fiver Forces Analysis of Europe Pharmacogenomics Market 38
Figure 14. Breakdown of Europe Pharmacogenomics Market by Service, 2019-2030, % of Revenue 42
Figure 15. Europe Addressable Market Cap in 2020-2030 by Service, Value ($ mn) and Share (%) 43
Figure 16. Europe Pharmacogenomics Market: Genotyping, 2019-2030, $ mn 44
Figure 17. Europe Pharmacogenomics Market: SNP Identification, 2019-2030, $ mn 45
Figure 18. Europe Pharmacogenomics Market: Diagnostics, 2019-2030, $ mn 46
Figure 19. Europe Pharmacogenomics Market: Other Services, 2019-2030, $ mn 48
Figure 20. Breakdown of Europe Pharmacogenomics Market by Technology, 2019-2030, % of Sales Revenue 49
Figure 21. Europe Addressable Market Cap in 2020-2030 by Technology, Value ($ mn) and Share (%) 50
Figure 22. Europe Pharmacogenomics Market: Polymerase Chain Reaction (PCR), 2019-2030, $ mn 51
Figure 23. Europe Pharmacogenomics Market: Microarray, 2019-2030, $ mn 52
Figure 24. Europe Pharmacogenomics Market: Sequencing, 2019-2030, $ mn 53
Figure 25. Europe Pharmacogenomics Market: Electrophoresis, 2019-2030, $ mn 54
Figure 26. Europe Pharmacogenomics Market: Mass Spectrometry, 2019-2030, $ mn 55
Figure 27. Europe Pharmacogenomics Market: Other Technologies, 2019-2030, $ mn 56
Figure 28. Breakdown of Europe Pharmacogenomics Market by Application, 2019-2030, % of Sales Revenue 57
Figure 29. Europe Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%) 58
Figure 30. Europe Pharmacogenomics Market: Oncology, 2019-2030, $ mn 59
Figure 31. Europe Pharmacogenomics Market: Infectious Diseases, 2019-2030, $ mn 60
Figure 32. Europe Pharmacogenomics Market: Neurology/Psychiatry, 2019-2030, $ mn 61
Figure 33. Europe Pharmacogenomics Market: Cardiovascular, 2019-2030, $ mn 63
Figure 34. Europe Pharmacogenomics Market: Pain Management, 2019-2030, $ mn 64
Figure 35. Europe Pharmacogenomics Market: Other Applications, 2019-2030, $ mn 65
Figure 36. Breakdown of Europe Pharmacogenomics Market by End User, 2019-2030, % of Revenue 66
Figure 37. Europe Addressable Market Cap in 2020-2030 by End User, Value ($ mn) and Share (%) 67
Figure 38. Europe Pharmacogenomics Market: Hospitals and Clinics, 2019-2030, $ mn 68
Figure 39. Europe Pharmacogenomics Market: Pharmaceutical Companies, 2019-2030, $ mn 69
Figure 40. Europe Pharmacogenomics Market: Research Institutes, 2019-2030, $ mn 70
Figure 41. Breakdown of European Pharmacogenomics Market by Country, 2019 and 2030, % of Revenue 72
Figure 42. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%) 73
Figure 43. Pharmacogenomics Market in Germany, 2019-2030, $ mn 74
Figure 44. Pharmacogenomics Market in UK, 2019-2030, $ mn 76
Figure 45. Pharmacogenomics Market in France, 2019-2030, $ mn 79
Figure 46. Pharmacogenomics Market in Spain, 2019-2030, $ mn 81
Figure 47. Pharmacogenomics Market in Italy, 2019-2030, $ mn 83
Figure 48. Pharmacogenomics Market in Russia, 2019-2030, $ mn 85
Figure 49. Pharmacogenomics Market in Rest of Europe, 2019-2030, $ mn 87
Figure 50. Growth Stage of Europe Pharmacogenomics Industry over the Forecast Period 89
Europe pharmacogenomics market accounted for $1,565.6 million in 2019 and will grow by 7.1% annually over 2020-2030 owing to the rising adoption of personalized medicine and usage of pharmacogenomics for drug discovery and development amid COVID-19 pandemic. Highlighted with 38 tables and 50 figures, this 125-page report “Europe Pharmacogenomics Market 2020-2030 by Service (Genotyping, SNP, Diagnostics), Technology (PCR, Microarray, Sequencing, Electrophoresis, MS), Application, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe pharmacogenomics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe pharmacogenomics market in every aspect of the classification from perspectives of Service, Technology, Application, End User, and Country. Based on Service, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Genotyping • SNP Identification • Diagnostics • Other Services Based on Technology, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Polymerase Chain Reaction (PCR) • Microarray • Sequencing • Electrophoresis • Mass Spectrometry • Other Technologies Based on Application, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Oncology • Infectious Diseases • Neurology/Psychiatry • Cardiovascular • Pain Management • Other Applications Based on End User, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Hospitals and Clinics • Pharmaceutical Companies • Research Institutes Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Spain • Italy • Russia • Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania) Detailed analysis and annual revenue 2019-2030 are available for each key national market. The breakdown of key national markets by Service, Technology, and Application over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Europe pharmacogenomics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): 23andMe, Inc. Abbott Laboratories Admera Health, LLC Agena Biosciences, Inc. Astra Zeneca PLC Bayer AG Becton, Dickinson and Company Cancer Genetics, Inc. Dynamic DNA Laboratories Empire Genomics LLC F. Hoffmann-La Roche Ltd geneOmbio Technologies Pvt Ltd. Genomic Health, Inc. Illumina, Inc. Laboratory Corporation of America Holdings Myriad Genetics Inc. Oneome LLC Opko Health, Inc. Pathway Genomics Corporation QIAGEN N.V. Quest Diagnostics Incorporated Teva Pharmaceuticals Industries Ltd. Thermo Fisher Scientific Inc. Transgenomic, Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More